Researchers at UC San Diego are developing a new drug to treat CLL. The drug, cirmutuzumab, is an antibody designed to attach to a protein on the surface of CLL cells. Researchers hope that this process will block cancerous cell growth and survival. Right now, cirmtuzumab is being tested for its safety and effectiveness in humans in a Phase One clinical trial. “A brand new way to target and kill blood cancer,” WNDU, features Thomas Kipps, MD, PhD.
(Source: http://www.utsandiego.com/news/2014/sep/17/ucsd-leukemia-cll-trial-kipps-cirm/, https://clinicaltrials.gov/ct2/show/NCT02222688?term=cirmtuzumab&rank=1 )